SABCS 2022 Conference Coverage


 

SABCS 2022 5-Year Results and Correlative Analyses From ATEMPT (TBCRC033): Adjuvant Trastuzumab Emtansine vs. Paclitaxel + Trastuzumab for Stage I HER2+ BC

278 views
December 13, 2022
Comments 0
Login to view comments. Click here to Login